Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

医学 塞库金单抗 阿达木单抗 银屑病性关节炎 皮肤病科 双盲 内科学 银屑病 关节炎 类风湿性关节炎 安慰剂 替代医学 病理
作者
Iain B. McInnes,Frank Behrens,Philip J. Mease,Arthur Kavanaugh,Christopher T. Ritchlin,Peter Nash,Jordi Gratacós,Philippe Goupille,Т. В. Коротаева,Alice B. Gottlieb,Ruvie Martin,Kevin Ding,Pascale Pellet,Shephard Mpofu,Luminita Pricop
出处
期刊:The Lancet [Elsevier BV]
卷期号:395 (10235): 1496-1505 被引量:282
标识
DOI:10.1016/s0140-6736(20)30564-x
摘要

Summary

Background

Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision making. The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab as first-line biological monotherapy for 52 weeks in patients with active psoriatic arthritis, with a musculoskeletal primary endpoint of American College of Rheumatology (ACR) 20 response.

Methods

This parallel-group, double-blind, active-controlled, phase-3b, multicentre (168 sites in 26 countries) trial enrolled patients aged at least 18 years with active psoriatic arthritis. Eligible patients were randomly assigned (1:1) by means of interactive response technology to receive secukinumab or adalimumab. Patients, investigators, site personnel, and those doing the assessments (except independent study drug administrators) were masked to study assignment. 300 mg secukinumab was administered subcutaneously at baseline, weeks 1, 2, 3, and 4, and then every 4 weeks until week 48 as a pre-filled syringe. Adalimumab was administered every 2 weeks from baseline until week 50 as 40 mg per 0·4 mL citrate free subcutaneous injection. The primary outcome was the proportion of patients with at least 20% improvement in the ACR response criteria (ACR20) at week 52. Patients were analysed according to the treatment to which they were randomly assigned. Safety analyses included all safety data reported up to and including the week 52 visit for each patient who received at least one dose of study drug. The trial is registered at ClinicalTrials.gov, NCT02745080.

Findings

Between April 3, 2017 and Aug 23, 2018, we randomly assigned 853 patients to receive secukinumab (n=426) or adalimumab (n=427). 709 (83%) of 853 patients completed week 52 of the study, of whom 691 (81%) received the last study treatment at week 50. 61 (14%) of 426 patients in the secukinumab group discontinued treatment by week 52 versus 101 (24%) of 427 patients in the adalimumab group. The primary endpoint of superiority of secukinumab versus adalimumab for ACR20 response at week 52 was not met. 67% of patients in the secukinumab group achieved an ACR20 response at week 52 versus 62% of patients in the adalimumab group (OR 1·30, 95% CI 0·98–1·72; p=0·0719). The safety profiles of secukinumab and adalimumab were consistent with previous reports. Seven (2%) of 426 patients in the secukinumab group and six (1%) of 427 patients in the adalimumab group had serious infections. One death was reported in the secukinumab group due to colon cancer and was assessed as not related to the study drug by the investigator.

Interpretation

Secukinumab did not meet statistical significance for superiority versus adalimumab in the primary endpoint of ACR20 response at week 52. However, secukinumab was associated with a higher treatment retention rate than adalimumab. This study provides comparative data on two biological agents with different mechanisms of action, which could help guide clinical decision making in the management of patients with psoriatic arthritis.

Funding

Novartis Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
小糖完成签到,获得积分10
刚刚
Masweet发布了新的文献求助10
1秒前
郭XX完成签到,获得积分10
1秒前
1秒前
1秒前
1秒前
2秒前
2秒前
十五完成签到 ,获得积分10
2秒前
初景发布了新的文献求助10
2秒前
无语的尔岚完成签到,获得积分10
2秒前
Sky完成签到,获得积分10
2秒前
Selonfer发布了新的文献求助30
2秒前
2秒前
小红牛完成签到,获得积分10
2秒前
无极微光的应助被开朗寇采纳,获得20
3秒前
777发布了新的文献求助10
3秒前
喝口可乐的应助被pc采纳,获得10
3秒前
雨天完成签到,获得积分10
3秒前
辛菜头完成签到,获得积分10
3秒前
zxn发布了新的文献求助10
4秒前
4秒前
谭筱妍完成签到,获得积分10
4秒前
无雨完成签到,获得积分10
4秒前
小糖发布了新的文献求助10
4秒前
RJX发布了新的文献求助10
4秒前
Wsh完成签到,获得积分10
4秒前
QJZ发布了新的文献求助10
4秒前
huihui发布了新的文献求助10
5秒前
Pan完成签到,获得积分10
5秒前
finish发布了新的文献求助10
5秒前
5秒前
wuyongxiang完成签到,获得积分10
5秒前
时刻保持质疑完成签到,获得积分10
5秒前
溪茵完成签到 ,获得积分10
5秒前
5秒前
星辰迷殇完成签到,获得积分10
6秒前
小鱼小鱼完成签到 ,获得积分10
6秒前
鳗鱼胜发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180531
求助须知:如何正确求助?哪些是违规求助? 9570507
关于积分的说明 21812974
捐赠科研通 7776619
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557539
邀请新用户注册赠送积分活动 2479185